Biodegradable polycarbonate-based nanogels loaded with anti-MFAP-5 siRNA for anti-angiogenic therapy in hepatocellular carcinoma
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e737
DOI: 10.1055/s-0044-1789916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von P. Schneider und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Background and aims : Proangiogenic microfibrillar-associated protein 5 (MFAP-5) is released from cancer-associated fibroblasts (CAF) in the tumor microenvironment and represents a target for antistromal therapy, which could be addressed by RNA interference (Kaps L, Schuppan D, cells, 2020; Duan Y, 2023 Oncogene). Biocompatible nanogels (NG) were loaded with siRNA to knockdown MFAP-5 in a murine model for HCC. Methods and results : 3T3-fibroblasts, as precursor cells for CAF in vitro, were activated in co-culture with HCC cells (Dt81Hepa1-6) to obtain a CAF-like phenotype, highly expressing MFAP-5. Anti-MFAP-5 siRNA loaded NG (NG:MFAP5-siRNA) induced a robust dose-dependent knockdown for MFAP-5 (-96% at 100 nM siRNA) in activated 3T3-fibroblasts as determined by RT-qPCR. For generation of liver tumors in fibrotic livers, C75BL/6 mice (8-10 WO, ♂︎) were gavaged with increasing doses of CCl4 for 6 weeks. Now, HCC cells were intrasplenically injected to develop HCC lesions exclusively in the fibrotic livers during 28 days. For biodistribution, HCC mice received an intravenous injection of NG loaded with fluorescently labeled Cy5.5-siRNA (NG:Cy5.5-siRNA) and monitored by IVIS imaging. Rapidly after injection, NG:Cy5.5-siRNA accumulated primarily in the liver and were efficiently taken up into CAF (α-SMA+)> dendritic cells (CD11c+)> macrophages (F4/80+) as quantified by flow cytometry of liver single-cell suspensions. For HCC therapy, mice (n=5) received three injections of NG:MFAP5-siRNA (1 or 2 mg/kg siRNA) at day 21, 23, 25 after HCC inoculation, while controls received encapsulated non-targeting control siRNA (scsiRNA). NG:MFAP5-siRNA treated mice had significantly less tumor burden compared to controls as reflected by lower liver weights (p
Zitieren
APA
Schneider, P., Fuchs, A., Czysch, C., Schunke, J., Fichter, M., Bolduan, V., Ludwig, N., Akilli-Öztürk, Ö., Schrörs, B., Durak, F., Diken, M., Schattenberg, J. M., Grabbe, S., Nuhn, L., & Kaps, L. (2024). Biodegradable polycarbonate-based nanogels loaded with anti-MFAP-5 siRNA for anti-angiogenic therapy in hepatocellular carcinoma. Zeitschrift für Gastroenterologie, 62(09), e737. https://doi.org/10.1055/s-0044-1789916
Vancouver
Schneider P, Fuchs A, Czysch C, Schunke J, Fichter M, Bolduan V, et al. Biodegradable polycarbonate-based nanogels loaded with anti-MFAP-5 siRNA for anti-angiogenic therapy in hepatocellular carcinoma. Zeitschrift für Gastroenterologie. 2024;62(09):e737. doi:10.1055/s-0044-1789916
BibTeX
@article{Schneider2024,
author = {Schneider, P. and Fuchs, A. and Czysch, C. and Schunke, J. and Fichter, M. and Bolduan, V. and Ludwig, N. and Akilli-Öztürk, Ö. and Schrörs, B. and Durak, F. and Diken, M. and Schattenberg, J. M. and Grabbe, S. and Nuhn, L. and Kaps, L.},
title = {Biodegradable polycarbonate-based nanogels loaded with anti-MFAP-5 siRNA for anti-angiogenic therapy in hepatocellular carcinoma},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {e737},
doi = {10.1055/s-0044-1789916}
}
EUVIMED